Business
-
Merxin Ltd and Perlen Packaging have announced that they will co-develop inhaled cannabis products based on Perlen’s BLISTair single use dry powder inhaler, with Merxin developing the formulations and marketing the cannabis DPIs. The BLISTair… Read more . . .
-
Opiant Pharmaceuticals said that it has discontinued development of OPNT001 naloxone nasal spray for the treatment of bulimia nervosa (BN) after a Phase 2 study failed to meet its primary endpoint. The company had announced… Read more . . .
-
Inhaled cannabinoid developer Senzer said that it believes the company is the first to receive ISO 13485:2016 certification for design and development of a pharmaceutical-grade cannabinoid delivery device. Senzer’s Systemic inhaled Delivery Device (SiDD) platform… Read more . . .
-
The US Patent and Trademark Office (USPTO) has granted OtiTopic, Inc. two patents covering its Asprihale (OTI-0726) inhaled aspirin formulation, which OtiTopic is developing as a rescue treatment for suspected myocardial infarction (MI), the company… Read more . . .
-
Inhaled liposomal ciprofloxacin developer Aradigm Corporation announced that it has filed for bankruptcy under Chapter 11 of the US Bankruptcy Code and plans to sell all of its assets. The company said that “Aradigm remains confident… Read more . . .
-
Glenmark Pharmaceuticals has announced that it plans to spin off a US-based company for development of innovative drugs, including GRC 39815, a retinoid-related orphan receptor gamma t (RORγt) inhibitor in pre-clinical development as a potential… Read more . . .
-
The US Patent and Trademark Office (USPTO) has provided VistaGen a notice of allowance regarding a patent covering the use of its PH10 nasal spray for the treatment of depression, the company said. VistaGen announced… Read more . . .
-
Both GSK and Mylan have announced the availability of generic versions of GSK’s Advair Diskus fluticasone propionate/salmeterol DPI in the US. GSK made a statement regarding its authorized generic on February 8, 2019, and Mylan… Read more . . .
-
Pulmatrix announced that it has received five new patents covering PUR1800 and PUR5700, which are inhaled narrow spectrum kinase inhibitors that Pulmatrix licensed from Janssen subsidiary RespiVert in June 2017. The new patents include two… Read more . . .
-
Orion and Propeller Health have announced that they will co-develop a custom sensor for Orion’s Easyhaler devices that will allow the inhalers to connect to Propeller’s digital inhaler monitoring platform. According to the companies, “Development… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland